Vitruvias Therapeutics thyroid tablets recalled for superpotent drug
Vitruvias Therapeutics is recalling Thyroid Tablets, USP 1/2 Grain (30 mg) because the tablets are superpotent—meaning they contain higher-than-intended levels of active ingredients. This lot was distributed nationwide. The affected lot number is 504950, expiring 09/30/2026.
From the FDA notice · Read the official notice ↗
What to do
- Check if you have lot #504950 of Vitruvias Therapeutics Thyroid Tablets, USP 1/2 Grain.
- Contact your pharmacy or doctor immediately if you have this lot.
- Do not stop taking your thyroid medication without speaking to your doctor first.
- Your doctor will advise whether to switch to a different lot or brand.
Is yours affected?
Compare your label or packaging with the recalled product.
- Product
- Thyroid Tablets, USP, 1/2 Grain (30 mg), Each tablet contains: levothyroxine (T4) 19 mcg, liothyronine (T3) 4.5 mcg, 100 Tablets, Rx only, Distributed by: Vitruvias Therapeutics, Auburn, AL 36830, Product of USA, NDC 69680-166-00.
- Sold in
- Nationwide
- Made for
- Adults (0 months and older)
Details
- Units affected
- 1955 bottles
- Illnesses reported
- None reported
- Manufactured in
- 778 N Dean Rd Ste 600, N/A, Auburn, AL, United States
- Classification
- Class I
- Recall number
- D-0866-2026
In the FDA's words
- Description
- Thyroid Tablets, USP, 1/2 Grain (30 mg), Each tablet contains: levothyroxine (T4) 19 mcg, liothyronine (T3) 4.5 mcg, 100 Tablets, Rx only, Distributed by: Vitruvias Therapeutics, Auburn, AL 36830, Product of USA, NDC 69680-166-00. Superpotent Drug Lot # 504950, Exp Date: 09/30/2026. Distribution: US Nationwide. Affected quantity: 1955 bottles
- Hazard
- Superpotent Drug